Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Dominica Health Times.
Press releases published on April 30, 2025
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing …
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
GlobeNewswire
·
April 30, 2025
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …
Larimar Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
April 30, 2025
FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end …
Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement
GlobeNewswire
·
April 30, 2025
Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreement Investments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long- …
XORTX Provides Update on FDA Type B Meeting Request
GlobeNewswire
·
April 30, 2025
● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical …
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
GlobeNewswire
·
April 30, 2025
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 …
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
GlobeNewswire
·
April 30, 2025
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial. OKYO Pharma plans to analyze the efficacy data from the 17 patients who …
PL BioScience Launches World’s Only Patented Gamma-irradiated Human Platelet Lysate
GlobeNewswire
·
April 30, 2025
New high-quality cell growth supplement for cell manufacturing applications including in regenerative medicine and cell therapies Human Platelet Lysate (HPL) offers a safer and sustainable alternative to Fetal Bovine/ Calf Serum (FBS/FCS) Gamma-irradiated …
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
GlobeNewswire
·
April 30, 2025
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma …
Mountainside Joins Northwell Direct Network to Offer Best-in-Class Addiction Treatment
GlobeNewswire
·
April 30, 2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Mountainside Treatment Center is pleased to be named an in-network provider with Northwell Direct, owned by Northwell Health, New York State’s largest healthcare provider and private employer. Northwell Direct …
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
GlobeNewswire
·
April 30, 2025
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the 16th Abu Dhabi Wound Care Conference. Media Snippet. Presented during the …
DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies
GlobeNewswire
·
April 30, 2025
AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, le produit phare de DEBx Medical, a obtenu le prix IIWCG Achievement Award 2025 récompensant l’innovation dans le domaine du soin des plaies lors de la 16e conférence d’Abu Dhabi sur le soin des …
Best Testosterone Booster Supplements For Men: New Report Reveals Which Products Actually Work.
GlobeNewswire
·
April 30, 2025
New York, April 30, 2025 (GLOBE NEWSWIRE) -- WhatBest, a trusted resource for product research and rankings, has officially announced its list of the top 5 best testosterone boosters for men, showcasing five high-performing supplements identified through …
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
GlobeNewswire
·
April 30, 2025
Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by …
Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast
GlobeNewswire
·
April 30, 2025
L’ensemble des résultats des parties d’escalade et d’expansion de dose de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) après chimiothérapie d’induction chez des patients atteints d’un cancer du pancréas localement avancé ou à la limite de la résécabilité …
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard - Au congrès annuel de l’AACR 2025
GlobeNewswire
·
April 30, 2025
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard Au congrès annuel de l’AACR 2025 Une nouvelle signature d’expression génique pour prédire la réponse clinique aux points de contrôle immunitaires …
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO
GlobeNewswire
·
April 30, 2025
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO New recruits expand senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the …
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
GlobeNewswire
·
April 30, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for …
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
GlobeNewswire
·
April 30, 2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of …
Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
GlobeNewswire
·
April 30, 2025
Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL), today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and …